Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;18(2):114-115.
doi: 10.1200/OP.21.00486. Epub 2021 Aug 27.

Evolving Treatment Paradigm in Frontline CLL

Nitin Jain  1
Affiliations
Comment

Evolving Treatment Paradigm in Frontline CLL

Nitin Jain. JCO Oncol Pract. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Nitin JainHonoraria: Pharmacyclics, ADC Therapeutics, Adaptive Biotechnologies, AbbVie/Genentech, Janssen, AstraZeneca/MedImmune, Servier, Precision Biosciences, BeiGene, TG Therapeutics, Cellectis, Bristol Myers Squibb/CelgeneConsulting or Advisory Role: Pharmacyclics, ADC Therapeutics, Adaptive Biotechnologies, AbbVie/Genentech, Janssen, AstraZeneca/MedImmune, Servier, Precision Biosciences, BeiGene, TG Therapeutics, Cellectis, Bristol Myers Squibb/CelgeneResearch Funding: Pfizer, Pharmacyclics, AbbVie, Genentech/Roche, Incyte, Infinity Pharmaceuticals, Bristol Myers Squibb, Seattle Genetics, Celgene, ADC Therapeutics, Servier, AstraZeneca/MedImmune, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics, fate therapeutics, Kite, a Gilead companyNo other potential conflicts of interest were reported.

Comment on

  • Frontline Management of CLL in 2021.
    Brem EA, O'Brien S. Brem EA, et al. JCO Oncol Pract. 2022 Feb;18(2):109-113. doi: 10.1200/OP.21.00258. Epub 2021 Jul 21. JCO Oncol Pract. 2022. PMID: 34288757 No abstract available.

MeSH terms

LinkOut - more resources